FOLFIRI-线治疗晚期胃癌50例临床观察  

Clinical evaluation of FOLFIRI as first-line therapy for patients with advanced gastric cancer

作　　者：龙建林[1] 易全会 任章霞[1] 杨宁[1] 

机构地区：[1]广安市人民医院肿瘤科,四川广安638000

出　　处：《西部医学》2010年第5期897-899,共3页Medical Journal of West China

摘　　要：目的观察伊立替康联合亚叶酸钙及氟尿嘧啶(FOLFIRI)一线治疗晚期胃癌的疗效、中位无进展生存时间(PFS)、总的生存时间(OS)及毒副作用。方法50例经过组织学证实的晚期胃癌患者接受FOLFIRI方案治疗,主要终点是:客观有效率(RR)、PFS、总生存时间(OS)及毒副反应。结果50例患者均可以接受疗效及生存评价,其中部分缓解(PR)23例(46.0%),稳定(SD)13例(26.0%),进展(PD)14例(28%),无CR病例。RR为46.0%,中位PFS时间为6.4个月,中位OS为10.6个月。结论FOLFIRI方案一线治疗局部晚期和转移性晚期胃癌能够提高RR、PFS及OS,副作用轻,耐受性好,可在临床推广应用。Objective To observe the response rate （RR）, median progression-free survival （PFS）, median overall survival （OS） and adverse effects of FOLFIRI as first-line therapy for patients with advanced gastric cancer. Methods 50 patients histologically and cytologically confirmed advanced gastric cancer were enrolled and received FOLFIRI regimen therapy. The primary endpoints were RR, median PFS, median OS and adverse effects. Results Of the 50 patients, 23 patients achieved PR （partial response）, 13 patients had SD （stable disease） and 14 patients had PD （progression disease）, no CR （complete response） was gained. The response rate was 46%, median PFS was 6.4 months and median OS was 10.6 months. Conclusion FOLFIRI as first-line therapy for patients with advanced gastric cancer could improved RR, median PFS and OS. The adverse effects were tolerable.

关 键 词：FOLFIRI 一线治疗 晚期胃癌 

分 类 号：R735.1[医药卫生—肿瘤]